GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
Dividend History
Investors can expect a dividend payout of $0.42 per share, scheduled to be distributed in 65 days on January 8, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 8, 2026 | $0.42 | 2025-11-14 | 2025-11-14 |
| October 9, 2025 | $0.43 | 2025-08-15 | 2025-08-15 |
| July 10, 2025 | $0.43 | 2025-05-16 | 2025-05-16 |
| April 10, 2025 | $0.41 | 2025-02-21 | 2025-02-21 |
| January 9, 2025 | $0.38 | 2024-11-15 | 2024-11-15 |
Dividends Summary
- GSK plc American Depositary Shares (Each representing two Ordinary Shares) has issued 92 dividend payments over the past 23 years
- The most recent dividend was paid 26 days ago, on October 9, 2025
- The highest dividend payed out to investors during this period was $0.75 per share
- The average dividend paid during this period was $0.49 per share.
Company News
The global anti-inflammatory drugs market is projected to grow from USD 132.63 billion in 2025 to USD 274.79 billion by 2034, driven by increasing chronic inflammatory diseases, innovations in biologics, and growing geriatric populations.
GSK reported strong Q3 results with sales of $11.53 billion, an 8% increase at constant currency. The company raised its 2025 financial guidance, expecting sales growth of 6-7% and core earnings per share increase of 10-12%.
Leon O. Moulder, CEO of Zenas BioPharma, purchased 36,928 shares through an open-market transaction and announced a licensing deal with InnoCare Pharma for a multiple sclerosis candidate, signaling confidence in the company's potential.
President Trump announced a 100% tariff on branded and patented pharmaceutical products starting October 1, 2025, causing significant market disruption and raising concerns about global pharmaceutical supply chains and trade policy.
Moderna's stock has outperformed the industry, sector, and S&P 500 in 2023, driven by the strong development of its mRNA-based therapeutics. The company plans to launch 15 new products, including an RSV vaccine, over the next five years, reducing its dependence on the COVID-19 vaccine. Moderna's robust pipeline progress and strong cash position m...